151 related articles for article (PubMed ID: 37803853)
1. [Interim results of a multicenter cohort study for Chinese Children Leukemia Group-acute lymphoblastic leukemia 2018 regimen].
Chinese Children Leukemia Group
Zhonghua Er Ke Za Zhi; 2023 Oct; 61(10):874-880. PubMed ID: 37803853
[No Abstract] [Full Text] [Related]
2. [Outcome of children with T cell acute lymphoblastic leukemia treated with Chinese Children Leukemia Group acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol].
Liu XM; Chen XJ; Zou Y; Wang SC; Wang M; Zhang L; Chen YM; Yang WY; Guo Y; Zhu XF
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):761-766. PubMed ID: 31594062
[No Abstract] [Full Text] [Related]
3. [Clinical Features and Prognosis of Acute T-cell Lymphoblastic Leukemia in Children--Multi-Center Data Analysis in Fujian].
Wu CP; Zheng YZ; Li J; Wen H; Weng KZ; Zhuang SQ; Wu XG; Hua XL; Zheng H; Chen ZS; LE SH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):6-13. PubMed ID: 38387892
[TBL] [Abstract][Full Text] [Related]
4. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
5. [Long-term outcome of childhood T-cell acute lymphoblastic leukemia treated with modified national protocol of childhood leukemia in China-acute lymphoblastic leukemia 2008].
Liao C; Shen DY; Xu XJ; Xu WQ; Zhang JY; Song H; Yang SL; Zhao FY; Shen HP; Tang YM
Zhonghua Er Ke Za Zhi; 2020 Sep; 58(9):758-763. PubMed ID: 32872717
[No Abstract] [Full Text] [Related]
6. [Clinical effect of CCLG-ALL2008 regimen in treatment of children and adolescents aged >10 years with acute lymphoblastic leukemia].
Lan Y; Chen XJ; Zou Y; Ruan M; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2019 May; 21(5):405-410. PubMed ID: 31104652
[TBL] [Abstract][Full Text] [Related]
7. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China.
Cui L; Li ZG; Chai YH; Yu J; Gao J; Zhu XF; Jin RM; Shi XD; Zhang LP; Gao YJ; Zhang RD; Zheng HY; Hu SY; Cui YH; Zhu YP; Zou Y; Ng MHL; Xiao Y; Li JH; Zhang YH; He HL; Xian Y; Wang TY; Li CK; Wu MY;
Am J Hematol; 2018 Jul; 93(7):913-920. PubMed ID: 29675840
[TBL] [Abstract][Full Text] [Related]
8. [Report of Chinese Children's Cancer Group acute lymphoblastic leukemia 2015 multicenter study].
Chinese Children′s Cancer Group Acute Lymphoblastic Leukemia 2015 Study Group
Zhonghua Er Ke Za Zhi; 2022 Oct; 60(10):1002-1010. PubMed ID: 36207846
[No Abstract] [Full Text] [Related]
9. [The Best Time of Minimal Residual Disease Monitoring for Predicting Survival and Prognosis in Children with T-Cell Acute Lymphoblastic Leukemia].
Bao H; Li TY; Wu YT; Xiao ZT; Zhang L; Luo LY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1471-1477. PubMed ID: 34627426
[TBL] [Abstract][Full Text] [Related]
10. [Long-Term Outcome of 940 Children with Newly Diagnosed Acute Lymphoblastic Leukemia Treated with CCLG-ALL 2008: A Prospective Single Center Study in China].
Zou Y; Chen XJ; Liu XM; Guo Y; Yang WY; Chen YM; Zhang L; Zhu XF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1075-1080. PubMed ID: 32798380
[TBL] [Abstract][Full Text] [Related]
11. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
[TBL] [Abstract][Full Text] [Related]
12. [Multicenter evaluation of minimal residual disease monitoring in early induction therapy for treatment of childhood acute lymphoblastic leukemia].
Wu XJ; Liao N; Mai HR; Li XY; Wan WQ; Yang LH; Huang LB; Luo XQ; Tian C; Chen QW; Long XJ; He YY; Wang Y; Li ZG; Xu HG
Zhonghua Er Ke Za Zhi; 2024 Mar; 62(4):337-344. PubMed ID: 38527504
[No Abstract] [Full Text] [Related]
13. [Clinical Characteristics and Treatment Efficacy of Children with SIL/TAL1 Positive T-Cell Acute Lymphoblastic Leukemia].
Liu X; Li WJ; Zhao XX; Gao C; Zhao W; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Zhou X; Wu MY; Cui L; Li ZG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):681-6. PubMed ID: 27342490
[TBL] [Abstract][Full Text] [Related]
14. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
[TBL] [Abstract][Full Text] [Related]
15. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
16. A prospective evaluation of minimal residual disease as risk stratification for CCLG-ALL-2008 treatment protocol in pediatric B precursor acute lymphoblastic leukemia.
Hu YX; Lu J; He HL; Wang Y; Li JQ; Xiao PF; Li J; Lv H; Sun YN; Fan JJ; Chai YH; Hu SY
Eur Rev Med Pharmacol Sci; 2016 May; 20(9):1680-90. PubMed ID: 27212157
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and prognostic factors of the chemotherapy regimen of CCLG-ALL-2008 on pediatric acute lymphoblastic leukemia with ETV6-RUNX1 rearrangement].
Liu F; Chen XJ; Guo Y; Yang WY; Chen X; Zhang XY; Zhang RR; Ren YY; Zhu XF
Zhonghua Xue Ye Xue Za Zhi; 2020 Nov; 41(11):896-902. PubMed ID: 33333691
[No Abstract] [Full Text] [Related]
18. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
[TBL] [Abstract][Full Text] [Related]
19. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of the efficacy of two chemotherapy protocols for children with TEL-AML1[STBZ] fusion gene positive acute lymphoblastic leukemia].
Wang KL; Mei YY; Cui L; Gao C; Liu FF; Zhao XX; Li WJ; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Wu MY; Zhou X; Li ZG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):285-90. PubMed ID: 24762993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
